US5204323A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Heparin and hirudin antidotal compositions and methods
Assignee: Novartis Corp
•
Filing: 1991-09-20
•
Granted: 1993-04-20
•
Expires: 2011-09-20
Abstract
Abstract The invention provides an antidote to blood anticoagulants comprising Factor VIII or fragments of Factor VIII which retain its activity or a substance which increases its concentration in blood.
Inventors
- 👤 Valerie S. Findlay
- 👤 Roger Kerry
- 👤 Graham F. Pay
- 👤 Robert B. Wallis
- 👤 Keith D. Butler
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 02:41
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/81; C07K14/815; A; A61; A61K; A61K35/00; A61K35/56; A61K35/62; A61K38/00; A61K38/04; A61K38/08; A61K38/09; A61K38/095; A61K38/16; A61K38/17; A61K38/36; A61K38/37
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
91 words
A method of at least partially reversing the anticoagulation activity of a blood anticoagulant in a mammal comprising administering to said mammal a therapeutically effective amount of Factor VIII or fragments of Factor VIII which retain its activity or a substance which increases its concentration in blood, wherein the blood anticoagulant is selected from the group consisting of heparin, anticoagulantly active heparin fragments, low molecular weight heparins, fragmin, thrombin inhibitors, hirudin, synthetic hirudin variants, hirudin derivatives, hirudin fragments, desulphatohirudin variants, (2R, 4R)-4-methyl-1-[N 2 -(3-(RS)-methyl-1,2,3,4-tetrahydro-8-quinolinyl-sulphonyl)-(S)-arginyl]-2-piperidine carboxylic acid, D-phenyl-alanyl-L-prolyl-L-arginine aldehyde sulphate, and Nα-(2-naphthalene-sulphonyl-glycyl)-4-amido-phenylalaninepiperidine.
Claim 2
Independent Claim
91 words
A method of at least partially reversing the anticoagulation activity of a blood anticoagulant in a mammal comprising administering to said mammal a therapeutically effective amount of Factor VIII or fragments of Factor VIII which retain its activity or a substance which increases its concentration in blood, wherein the blood anticoagulant is selected from the group consisting of heparin, anticoagulantly active heparin fragments, low molecular weight heparins, fragmin, thrombin inhibitors, hirudin, synthetic hirudin variants, hirudin derivatives, hirudin fragments, desulphatohirudin variants, (2R, 4R)-4-methyl-1-[N 2 -(3-(RS)-methyl-1,2,3,4-tetrahydro-8-quinolinyl-sulphonyl)-(S)-arginyl]-2-piperidine carboxylic acid, D-phenyl-alanyl-L-prolyl-L-arginine aldehyde sulphate, and Nα-(2-naphthalene-sulphonyl-glycyl)-4-amido-phenylalaninepiperidine.
Claim 3
Dependent Claim
10 words
The method of claim 1, wherein the anticoagulant is hirudin.
Claim 4
Dependent Claim
28 words
The method of claim 1, wherein the anticoagulant is selected from the group consisting of heparin, anticoagulantly active heparin fragments, low molecular weight heparins, fragmin, and thrombin inhibitors.
Claim 5
Dependent Claim
25 words
The method of claim 1, wherein the anticoagulant is selected from the group consisting of low molecular weight heparins, and low molecular weight thrombin inhibitors.
Claim 6
Dependent Claim
28 words
The method of claim 1, wherein the anticoagulant is selected from the group consisting of hirudin, synthetic hirudin, variants, derivatives and fragments thereof and desulphatohirudin variants and derivatives.
Claim 7
Dependent Claim
11 words
The method of claim 1, wherein the anticoagulant is desulphatohirudin HV1.
Claim 8
Dependent Claim
10 words
The method of claim 1, wherein the anticoagulant is heparin.
Claim 9
Dependent Claim
10 words
The method of claim 1, wherein the anticoagulant is fragmin.
Claim 10
Dependent Claim
31 words
The method of claim 1, wherein the anticoagulant is a low molecular weight thrombin inhibitor selected from the group consisting of (2R,4R)-4-methyl-1-[N 2 -(3-(RS)-methyl-1,2,3,4-tetrahydro-8-quinolinyl-sulphonyl)-(S)-arginyl]-2-piperidine carboxylic acid, D-phenyl-alanyl-L-prolyl-L-arginine aldehyde sulphate, and Nα-(2-naphthalenesulphonyl-glycyl)-4-amido-phenylalanine-piperidine.
Claim 11
Dependent Claim
15 words
The method of claim 1, wherein, the substance which increases Factor VIII is 1-deamino-8-D-arginine vasopressin.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-19 | 1996-10-19 | 1997-04-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-19 | 2000-10-19 | 2001-04-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-19 | 2004-10-19 | 2005-04-20 | $7700.00 | Window Closed / Lapsed |